Lin Qingxuan Commences Subscription Today: Reality Challenges Behind the High-Growth Halo of China

ZC Asia has learnt that Shanghai Lin Qingxuan Cosmetics Group Co., Ltd. (hereinafter referred to as ‘Lin Qingxuan’) commenced its subscription period from 18 to 23 December, with plans to list on the Main Board of the Hong Kong Stock Exchange on 30 December under stock code 02657.

As China's leading domestic premium skincare brand by retail value, the company has achieved remarkable performance growth in recent years, driven by its flagship product, the Camellia Anti-Wrinkle Repairing Essence Oil. The prospectus reveals that Lin Qingxuan's revenue for the first half of 2025 surpassed the RMB 1 billion threshold for the first time, representing a year-on-year increase of 98.3%. The overall gross profit margin remained at a robust 82.4%, demonstrating the profit resilience characteristic of premium skincare brands.

For this global offering, Lin Qingxuan has set the issue price at HK$77.77 per share, with net proceeds expected to reach approximately HK$997 million. The company has successfully secured several prominent institutions, including Fidelity Investments, Zhengxin Valley Capital, and Great Life Insurance, as cornerstone investors, signalling capital markets' anticipation for the domestic skincare sector. The prospectus discloses that proceeds will primarily fund brand development, sales network expansion, and enhancements to R&D and production capabilities.

Increasing Reliance on Core Products, Second Growth Curve Yet to Materialise

The prospectus indicates that the revenue contribution from its flagship product, the ‘Camellia Anti-Wrinkle Repairing Essence Oil’, has risen steadily from 31.5% in 2022 to 45.5% in the first half of 2025. This signifies a highly concentrated growth engine, with nearly half of the company's revenue dependent on a product launched over a decade ago.

Despite ongoing efforts to expand its product portfolio—including launches such as the Black Gold Cream and high-SPF sunscreens—these emerging offerings have yet to establish themselves as a robust second growth driver in terms of sales scale and market influence. This poses challenges for achieving balanced development across future product lines.

Concurrently, the company's sales channel structure has undergone a fundamental shift. Online channels have evolved from a supplementary role to the dominant force, with their revenue contribution surging from 45.1% to 65.4% within just three years. The Douyin platform has emerged as the core growth driver, with sales leaping from approximately ¥80 million to ¥350 million within a single year.

This rapid pivot in channel focus has delivered substantial traffic dividends and accelerated growth momentum. However, it has also drawn the company deeper into the price wars and traffic volatility inherent to online platforms. The aggressive promotions typical of online channels have created a significant gap between official product pricing and actual transaction values, posing a long-term challenge to the company's carefully constructed premium brand pricing structure.

Declining R&D expenditure raises sustainability concerns over premium positioning

The cornerstone of Lin Qingxuan's positioning as a ‘premium domestic skincare brand’ lies in its technological and R&D capabilities. However, financial data reveals a pronounced bias in resource allocation. From 2022 to the first half of 2025, the company's cumulative R&D expenditure totalled RMB 89.301 million, while sales and distribution expenses reached RMB 1.121 billion over the same period – 12.6 times the former.

The proportion of R&D expenditure relative to revenue shows a declining trend, falling from 3.06% in 2022 to 1.71% in the first half of 2025. This level of investment falls short compared to international premium cosmetics groups like L'Oréal, which typically allocate around 3%-4% of revenue to R&D.

Within the company's workforce structure, R&D personnel constitute merely 3.5% of employees, whereas sales and marketing staff account for a substantial 83.7%. This allocation further underscores the operational focus.

The relatively weak R&D investment correlates with the company's recurrent compliance issues concerning promotional claims. Historical records indicate that both the company and its founder have faced administrative penalties from market regulators for employing promotional claims such as ‘anti-ageing’ that exceeded approved product registrations. Although rectified, such incidents inevitably raise concerns about the long-term brand reputation management capabilities of an enterprise striving to cultivate a premium, professional, and trustworthy image.

Lin Qingxuan's prospectus references ‘premium’ over 150 times, underscoring its core market positioning. Presently, China's high-end skincare market remains predominantly dominated by international brands, presenting significant challenges for domestic brands seeking upward breakthroughs.

Notably, international beauty giant L'Oréal Group has strategically invested in Lin Qingxuan through its fund. This move not only signifies recognition of the brand's market standing but also foreshadows increasingly complex and multifaceted competition and collaboration within the sector. Concurrently, other domestic brands are accelerating their expansion into niche segments such as ‘oil-based skincare,’ intensifying the competitive landscape.

Disclaimer: The content herein is for reference only and does not constitute any form of investment advice. Should any information contained herein prove inaccurate, incomplete, or potentially misleading, please refer to the company's official announcements. Market risks exist; investment requires caution.